Fate Therapeutics Inc (FATE)

[jondoeuk]

(OT): HebeCell raised a $53M Series A https://www.businesswire.com/news/home/20210831005965/en/HebeCell-Raises-53-Million-in-Series-A-Financing-to-Advance-Unique-Off-The-Shelf-PSC-CAR-NK-Products-Into-Clinics



Around 80% of the iPSC-derived CD56+ NK cells also express CD8a as compared with ~30 of PB CD56+ NK cells https://academic.oup.com/stcltm/article/10/s2/S10/6522039

CD56+CD3-CD8a+ NK cells are more cytotoxic than CD56+CD3-CD8a-, indicating iPSC-derived NK cells posses stronger cell killing activity than regular peripheral blood NK cells. There is also both in vitro and in vivo (human) data from other groups https://onlinelibrary.wiley.com/doi/10.1002/cyto.990110316 https://pubmed.ncbi.nlm.nih.gov/1281676/ https://www.nature.com/articles/1700756 https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2141.2002.03495.x